Content about morphine sulfate

November 4, 2013

The Food and Drug Administration has approved a new injectable painkiller made by Becton, Dickinson and Co., the medical products manufacturer said Monday.

FRANKLIN LAKES, N.J. — The Food and Drug Administration has approved a new injectable painkiller made by Becton, Dickinson and Co., the medical products manufacturer said Monday.

BD announced the FDA approval of morphine sulfate injection as part of its BD Simplist line of ready-to-administer pre-filled injectables. The drug was approved in the 2-mg-per-mL, 4-mg-per-mL, 5-mg-per-mL, 8-mg-per-mL and 10-mg-per-mL strengths.

September 3, 2013

A new opioid painkiller drug made by Upsher-Smith Labs will become available on Wednesday, the drug maker said.

MAPLE GROVE, Minn. — A new opioid painkiller drug made by Upsher-Smith Labs will become available on Wednesday, the drug maker said.

Upsher-Smith said it would launch its morphine sulfate extended-release capsules in the 10-mg, 20-mg, 30-mg, 50-mg, 60-mg, 80-mg and 100-mg strengths.

The company said its product would be the first generic entrant for the 10-mg extended-release capsule dosage strength, adding that there have historically been a limited number of morphine sulfate generics available.

 

September 18, 2012

Generic drug makers Hospira, Sagent Pharmaceuticals and Teva Pharmaceutical Industries have launched generic versions of a chemotherapy drug made by Sanofi, the three companies said last month.


NEW YORK — Generic drug makers Hospira, Sagent Pharmaceuticals and Teva Pharmaceutical Industries have launched generic versions of a chemotherapy drug made by Sanofi, the three companies said last month.


August 8, 2012

The Food and Drug Administration has approved an oral painkiller made by Perrigo, the drug maker said Wednesday.

ALLEGAN, Mich. — The Food and Drug Administration has approved an oral painkiller made by Perrigo, the drug maker said Wednesday.

Perrigo announced the approval of morphine sulfate oral solution in the 100-mL/5% strength. The drug is a Schedule II controlled substance and is used to treat moderate to severe acute and chronic pain. Sales of the drug are about $26 million per year, according to Wolters Kluwer Health. Perrigo said it would ship the drug immediately.

December 22, 2011

A Pfizer painkiller appears to produce a much less positive experience for recreational drug users when crushed than when administered whole, according to results of a post-marketing clinical study program.

NEW YORK — A Pfizer painkiller appears to produce a much less positive experience for recreational drug users when crushed than when administered whole, according to results of a post-market clinical study program.

November 15, 2011

Actavis has launched an authorized generic drug for treating pain, the company said.

MORRISTOWN, N.J. — Actavis has launched an authorized generic drug for treating pain, the company said.

The drug maker announced Friday that it had started shipping morphine sulfate extended-release capsules, an authorized generic version of Kadian, which it also manufactures. The authorized generic product was launched on the same day as Watson Pharmaceuticals' generic version.

November 11, 2011

Watson Pharmaceuticals has launched its generic version of an opioid drug for treating pain, the company said Thursday.

PARSIPPANY, N.J. — Watson Pharmaceuticals has launched its generic version of an opioid drug for treating pain, the company said Thursday.

Watson announced the Food and Drug Administration approval and launch of morphine sulfate extended-release capsules.

The drug is a generic version of Actavis' Kadian, which had sales of about $275 million during the 12-month period ended in September, according to IMS Health.

October 27, 2011

Mylan has received final approval from the Food and Drug Administration for a drug designed to treat moderate to severe pain.

PITTSBURGH — Mylan has received final approval from the Food and Drug Administration for a drug designed to treat moderate to severe pain.

Mylan said its abbreviated new drug application for morphine sulfate extended-release tablets in the 15-mg, 30-mg, 60-mg, 100-mg and 200-mg strengths was approved by the FDA. The opioid analgesic is a generic version of Purdue Pharma's MS Contin. Mylan said it is launching the product immediately.

Morphine sulfate ER tablets had U.S. sales of approximately $173 million for the 12 months ended in June, according to IMS Health.

October 7, 2011

Watson Pharmaceuticals is looking to become the first to market a generic version of a painkiller made by Pfizer, the drug maker said Friday.

PARSIPPANY, N.J. — Watson Pharmaceuticals is looking to become the first to market a generic version of a painkiller made by Pfizer, the drug maker said Friday.

Watson said it filed a regulatory approval application with the Food and Drug Administration for morphine sulfate and naltrexone hydrochloride extended-release capsules in the 30-mg/1.2-mg, 50-mg/2-mg, 60-mg/2.4-mg, 80-mg/3.2-mg and 100-mg/4-mg strengths. The drug is a generic version of Embeda, made by Pfizer subsidiary King Pharmaceuticals.

August 12, 2011

Lannett announced that it has started shipping morphine sulfate oral solution, a painkiller approved by the Food and Drug Administration in June.

PHILADELPHIA—Lannett has started shipping a painkiller product approved by the Food and Drug Administration in June, the company said.

Lannett announced the shipment of morphine sulfate oral solution. Lannett sought FDA approval using a 505(b)(2) new drug application. Sales of morphine sulfate oral solution at average wholesale price were $31.7 million during the 12-month period ending in June, according to Wolters Kluwer.

June 7, 2011

Generic drug maker Lannett said that the Food and Drug Administration has assigned a Prescription Drug User Fee Act action date for one of Lannett's drugs.

PHILADELPHIA — Generic drug maker Lannett said that the Food and Drug Administration has assigned a Prescription Drug User Fee Act action date for one of Lannett's drugs.

The FDA said it revised its PDUFA goal date of June 23 for Lannett's new drug application for morphine sulfate oral solution.

"With a revised PDUFA date in 17 days, we are preparing for the relaunch of our morphine sulfate oral solution product, if approved,” Lannett president and CEO Arthur Bedrosian said.